137 related articles for article (PubMed ID: 37682791)
1. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
Yamshon S; Chen GZ; Gribbin C; Christos P; Shah B; Schuster SJ; Smith SM; Svoboda J; Furman RR; Leonard JP; Martin P; Ruan J
Blood Adv; 2023 Nov; 7(21):6579-6588. PubMed ID: 37682791
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1084-e1091. PubMed ID: 36180329
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
10. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y; Hagemeister FB; Westin JR; Fowler N; Samaniego F; Steiner R; Nair R; Iyer SP; Navsaria L; Badillo M; ; Feng L; Xuelin H; Nogueras Gonzalez GM; Xu G; Wagner-Bartak N; Thirumurthi S; Santos D; Tang G; Lin P; Wang SA; Jorgensen J; Yin CC; Li S; Patel KP; Vega F; Medeiros LJ; Flowers CR; Wang L
Lancet Oncol; 2022 Mar; 23(3):406-415. PubMed ID: 35074072
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
[TBL] [Abstract][Full Text] [Related]
15. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
17. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Evens AM; Hong F; Habermann TM; Advani RH; Gascoyne RD; Witzig TE; Quon A; Ranheim EA; Ansell SM; Cheema PS; Dy PA; O'Brien TE; Winter JN; Cescon TP; Chang JE; Kahl BS
Clin Cancer Res; 2020 Sep; 26(17):4468-4477. PubMed ID: 32532790
[TBL] [Abstract][Full Text] [Related]
18. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Phillips TJ; Bond D; Takiar R; Kump K; Kandarpa M; Boonstra P; Mayer TL; Nachar V; Wilcox RA; Carty SA; Karimi YH; Nikolovska-Coleska Z; Kaminski MS; Herrera AF; Maddocks K; Popplewell L; Danilov AV
Blood Adv; 2023 Aug; 7(16):4518-4527. PubMed ID: 37013954
[TBL] [Abstract][Full Text] [Related]
19. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
20. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
